We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Treatment of post‐transfusion hyperhaemolysis syndrome in Sickle Cell Disease with the anti‐IL6R humanised monoclonal antibody Tocilizumab.
- Authors
Sivapalaratnam, Suthesh; Linpower, Lisa; Sirigireddy, Bala; Agapidou, Alexandra; Jain, Susan; Win, Nay; Tsitsikas, Dimitris A.
- Abstract
Treatment of post-transfusion hyperhaemolysis syndrome in Sickle Cell Disease with the anti-IL6R humanised monoclonal antibody Tocilizumab It is characterised by brisk haemolysis of both transfused and recipient red cells, also known as "By-stander" haemolysis, with a haemoglobin (Hb) drop below pre-transfusion levels, marked increase in serum ferritin (SF) and a fall in reticulocyte count. 1 Hb, haemoglobin, LDH, lactate dehydrogenase; PTHS, post-transfusion hyperhaemolysis syndrome; RTC, reticulocytes; SF, serum ferritin.
- Publication
British Journal of Haematology, 2019, Vol 186, Issue 6, pe212
- ISSN
0007-1048
- Publication type
Academic Journal
- DOI
10.1111/bjh.16103